Unknown PHASE1 INTERVENTIONAL 1-arm NCT04213404

Ribociclib and Spartalizumab in R/M HNSCC (RISE-HN)

Ribociclib and Spartalizumab for Head and Neck Squamous Cell Carcinoma, a Phase I Study With Expansion Cohort (RISE-HN)

Sponsor: National Taiwan University Hospital

Conditions Head and Neck Squamous Cell Carcinoma

Updated 7 times since 2020 Last updated: Apr 19, 2022 Started: Mar 13, 2020 Primary completion: Jan 31, 2024 Completion: Jan 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Head and Neck Squamous Cell Carcinoma and is currently ongoing. National Taiwan University Hospital leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Feb 2025 — Present [monthly]

Unknown PHASE1

Status: Active Not Recruiting → Unknown
Sep 2024 — Feb 2025 [monthly]

Active Not Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1
May 2022 — Jul 2024 [monthly]

Active Not Recruiting PHASE1
Mar 2021 — May 2022 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 2 earlier versions

Jan 2021 — Mar 2021 [monthly]

Recruiting PHASE1
Jan 2020 — Jan 2021 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Taiwan University Hospital
Novartis

Data source: National Taiwan University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taipei, Taiwan